FMC-376 is under clinical development by Frontier Medicines and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FMC-376’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FMC-376 overview
FMC-376 is under development for the treatment of KRASG12C mutant metastatic solid tumors including non-small cell lung, metastatic pancreatic and metatstatic colorectal cancers. The drug candidates act by targeting activated KRAS G12C. It is developed based on chemoproteomics platform. It is administered through oral route.
Frontier Medicines overview
Frontier Medicines, is a biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. The company is headquartered in Boston, Massachusetts, the US.
For a complete picture of FMC-376’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.